Oil Prices Slide as U.S. Eyes Iranian Supply Relief Amid Middle East Tensions 
Trump Issues 48-Hour Ultimatum to Iran Over Strait of Hormuz, Threatens Power Grid Strikes 
HSBC Considers Cutting 20,000 Jobs Amid AI-Driven Transformation 
Elliott Investment Management Takes Multibillion-Dollar Stake in Synopsys 
Dollar Weakens as Middle East War Reshapes Global Rate Expectations 
US-Iran War: Trump Eyes Military Exit as Markets React to Potential De-escalation 
Iran War Fears Send Oil Prices Surging as U.S. Weighs Ground Troop Deployment 
Saudi Arabia Warns Oil Prices Could Surge Past $180 a Barrel Amid U.S.-Israel-Iran Conflict 
Tesla Eyes $2.9 Billion in Chinese Solar Equipment to Power 100 GW U.S. Manufacturing Push 
Asian Currencies Slide as Oil Prices Surge Amid U.S.-Israel-Iran Conflict 
U.S.-Iran War Escalates: Marines Deploy, Strait of Hormuz Closure Drives Global Oil Crisis 
Federal Reserve Crisis: DOJ Standoff Threatens Powell's Succession and Rate Stability 
Trump Signals End of U.S. Military Campaign Against Iran as Markets Rally 
Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
